Compare VRTX & LOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | LOW |
|---|---|---|
| Founded | 1989 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | RETAIL: Building Materials |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 122.4B |
| IPO Year | 2007 | 1994 |
| Metric | VRTX | LOW |
|---|---|---|
| Price | $517.10 | $221.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 35 |
| Target Price | ★ $595.36 | $249.48 |
| AVG Volume (30 Days) | 1.3M | ★ 2.9M |
| Earning Date | 11-02-2026 | 11-18-2026 |
| Dividend Yield | N/A | ★ 2.28% |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 10.90 | 7.17 |
| Revenue | $2,488,652,000.00 | ★ $86,286,000,000.00 |
| Revenue This Year | $10.46 | $7.05 |
| Revenue Next Year | $10.53 | $2.12 |
| P/E Ratio | $47.77 | ★ $30.56 |
| Revenue Growth | ★ 46.20 | 3.12 |
| 52 Week Low | $412.27 | $178.45 |
| 52 Week High | $568.67 | $293.06 |
| Indicator | VRTX | LOW |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 56.69 |
| Support Level | $493.75 | $203.60 |
| Resistance Level | $536.58 | $224.43 |
| Average True Range (ATR) | 15.90 | 6.39 |
| MACD | -3.73 | -1.34 |
| Stochastic Oscillator | 4.74 | 42.00 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Lowe's is the second-largest home improvement retailer globally, with 1,761 stores in the US, after the 2023 divestiture of its Canadian locations. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two-thirds of products sold. Lowe's primarily targets retail do-it-yourself (more than 60% of sales) and do-it-for-me customers, but has expanded its professional business clients to more than 30% from less than 20% in the past seven years (set to expand further with growth of FBM locations). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.